FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006378967> ?p ?o ?g. }

• W3006378967 endingPage "153303381988689" @default.
• W3006378967 startingPage "153303381988689" @default.
• W3006378967 abstract "Background: Association of drugs acting against different antiangiogenic mechanisms may increase therapeutic effect and reduce resistance. Noninvasive monitoring of changes in the antiangiogenic response of individual tumors could guide selection and administration of drug combinations. Noninvasive detection of early therapeutic response during dual, vertical targeting of the vascular endothelial growth factor pathway was investigated in an ectopic subcutaneous xenograft model for human pancreatic tumor. Methods: Dynamic contrast-enhanced ultrasound 12 MHz was used to monitor tumor-bearing Naval Medical Research Institute mice beginning 15 days after tumor implantation. Mice received therapy from 15 to 29 days with sorafenib (N = 9), ziv-aflibercept (N = 11), combined antiangiogenic agents (N = 11), and placebo control (N = 14). Sorafenib (BAY 43-9006; Nexavar), a multikinase inhibitor acting on Raf kinase and receptor tyrosine kinases—including vascular endothelial growth factor receptors 2 and 3—was administered daily (60 mg/kg, per os). Ziv-aflibercept (ZALTRAP), a high-affinity ligand trap blocking the activity of vascular endothelial growth factor A, vascular endothelial growth factor B, and placental growth factor was administered twice per week (40 mg/kg, intraperitoneally). Results: Functional evaluation with dynamic contrast-enhanced ultrasound indicated stable tumor vascularization for the control group while revealing significant and sustained reduction after 1 day of therapy in the combined group ( P = .007). There was no survival benefit or penalty due to drug combination. The functional progression-free survival assessed with dynamic contrast-enhanced ultrasound was significantly higher for the 3 treated groups; whereas, the progression-free survival based on tumor size did not discriminate therapeutic effect. Conclusions: Dynamic contrast-enhanced ultrasound, therefore, presents strong potential to monitor microvascular modifications during antiangiogenic therapy, a key role to monitoring antiangiogenic combining therapy to adapt dose range drug." @default.
• W3006378967 created "2020-02-24" @default.
• W3006378967 creator A5002529509 @default.
• W3006378967 creator A5005499018 @default.
• W3006378967 creator A5034292177 @default.
• W3006378967 creator A5038917187 @default.
• W3006378967 creator A5044158122 @default.
• W3006378967 creator A5059827260 @default.
• W3006378967 creator A5063195568 @default.
• W3006378967 creator A5072809739 @default.
• W3006378967 creator A5085728469 @default.
• W3006378967 date "2020-01-01" @default.
• W3006378967 modified "2023-10-09" @default.
• W3006378967 title "Monitoring Dual VEGF Inhibition in Human Pancreatic Tumor Xenografts With Dynamic Contrast-Enhanced Ultrasound" @default.
• W3006378967 cites W1573363574 @default.
• W3006378967 cites W1971837077 @default.
• W3006378967 cites W1980725734 @default.
• W3006378967 cites W1992387661 @default.
• W3006378967 cites W1995246862 @default.
• W3006378967 cites W1999966467 @default.
• W3006378967 cites W2005215351 @default.
• W3006378967 cites W2012922302 @default.
• W3006378967 cites W2048362401 @default.
• W3006378967 cites W2066697593 @default.
• W3006378967 cites W2071266566 @default.
• W3006378967 cites W2072810564 @default.
• W3006378967 cites W2091599051 @default.
• W3006378967 cites W2094785364 @default.
• W3006378967 cites W2102540838 @default.
• W3006378967 cites W2105651363 @default.
• W3006378967 cites W2113437226 @default.
• W3006378967 cites W2113980589 @default.
• W3006378967 cites W2115735904 @default.
• W3006378967 cites W2119281341 @default.
• W3006378967 cites W2126275851 @default.
• W3006378967 cites W2126393213 @default.
• W3006378967 cites W2136954135 @default.
• W3006378967 cites W2138378598 @default.
• W3006378967 cites W2139248078 @default.
• W3006378967 cites W2140765540 @default.
• W3006378967 cites W2143743735 @default.
• W3006378967 cites W2145835533 @default.
• W3006378967 cites W2149456801 @default.
• W3006378967 cites W2154493372 @default.
• W3006378967 cites W2156653782 @default.
• W3006378967 cites W2157769714 @default.
• W3006378967 cites W2160013345 @default.
• W3006378967 cites W4230026896 @default.
• W3006378967 doi "https://doi.org/10.1177/1533033819886896" @default.
• W3006378967 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7026814" @default.
• W3006378967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32065066" @default.
• W3006378967 hasPublicationYear "2020" @default.
• W3006378967 type Work @default.
• W3006378967 sameAs 3006378967 @default.
• W3006378967 citedByCount "2" @default.
• W3006378967 countsByYear W30063789672021 @default.
• W3006378967 countsByYear W30063789672022 @default.
• W3006378967 crossrefType "journal-article" @default.
• W3006378967 hasAuthorship W3006378967A5002529509 @default.
• W3006378967 hasAuthorship W3006378967A5005499018 @default.
• W3006378967 hasAuthorship W3006378967A5034292177 @default.
• W3006378967 hasAuthorship W3006378967A5038917187 @default.
• W3006378967 hasAuthorship W3006378967A5044158122 @default.
• W3006378967 hasAuthorship W3006378967A5059827260 @default.
• W3006378967 hasAuthorship W3006378967A5063195568 @default.
• W3006378967 hasAuthorship W3006378967A5072809739 @default.
• W3006378967 hasAuthorship W3006378967A5085728469 @default.
• W3006378967 hasBestOaLocation W30063789671 @default.
• W3006378967 hasConcept C126322002 @default.
• W3006378967 hasConcept C167734588 @default.
• W3006378967 hasConcept C170493617 @default.
• W3006378967 hasConcept C2775960820 @default.
• W3006378967 hasConcept C2776694085 @default.
• W3006378967 hasConcept C2776871010 @default.
• W3006378967 hasConcept C2777025900 @default.
• W3006378967 hasConcept C2777802072 @default.
• W3006378967 hasConcept C2778019345 @default.
• W3006378967 hasConcept C2778695046 @default.
• W3006378967 hasConcept C2778749236 @default.
• W3006378967 hasConcept C2780394083 @default.
• W3006378967 hasConcept C502942594 @default.
• W3006378967 hasConcept C71924100 @default.
• W3006378967 hasConcept C98274493 @default.
• W3006378967 hasConceptScore W3006378967C126322002 @default.
• W3006378967 hasConceptScore W3006378967C167734588 @default.
• W3006378967 hasConceptScore W3006378967C170493617 @default.
• W3006378967 hasConceptScore W3006378967C2775960820 @default.
• W3006378967 hasConceptScore W3006378967C2776694085 @default.
• W3006378967 hasConceptScore W3006378967C2776871010 @default.
• W3006378967 hasConceptScore W3006378967C2777025900 @default.
• W3006378967 hasConceptScore W3006378967C2777802072 @default.
• W3006378967 hasConceptScore W3006378967C2778019345 @default.
• W3006378967 hasConceptScore W3006378967C2778695046 @default.
• W3006378967 hasConceptScore W3006378967C2778749236 @default.
• W3006378967 hasConceptScore W3006378967C2780394083 @default.
• W3006378967 hasConceptScore W3006378967C502942594 @default.
• W3006378967 hasConceptScore W3006378967C71924100 @default.
• W3006378967 hasConceptScore W3006378967C98274493 @default.

• next